Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA to Acquire IntegraGen for €14.5M

NEW YORK – Belgian molecular diagnostics firm OncoDNA has filed a friendly cash tender offer to acquire French firm IntegraGen for €14.5 million ($16.4 million).

OncoDNA has offered to purchase the bioinformatics and genomic services firm at a price of €2.20 per share, representing a premium of more than 36 percent over the last closing price of IntegraGen shares on the Euronext Growth market of Euronext Paris.

Subject to the approval of the Autorité des Marchés Financiers (AMF) and pursuant to applicable regulations to foreign investment control in France, the offer will be opened at the end of the third quarter of 2020.

The firms plan to integrate their service offerings by combining DNA sequencing services and the bioinformatics tools developed by IntegraGen with the portfolio of oncology laboratory tests offered by OncoDNA.

OncoDNA and IntegraGen said that they believe the offer will allow them to provide a unique range of services and software solutions to clinicians, oncologists, researchers, and biologists worldwide. The acquisition will also help the team leverage a proprietary database that includes patient follow-up capabilities and artificial intelligence.

"We are very happy to announce this friendly takeover bid that will bring together IntegraGen's know-how in sequencing services and bioinformatics analyses with our expertise in oncology clinical interpretation," Jean-Pol Detiffe, OncoDNA CEO and founder, said in a statement. "We will integrate the entire chain of genomic operations and benefit from having a large-scale production capability ready for tomorrow's analyses, namely the complete sequencing of the tumor."

IntegraGen CEO Bernard Courtieu added that OncoDNA's international presence will allow IntegraGen to fully exploit its sequencing capabilities.

OncoDNA previously raised €19 million in a Series B financing round in February in order to support its international growth, accelerate software development, and expand its workforce.

For more details about the acqusition, click here.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more